Breakthrough in GMP-compliant iPSC therapy for recessive dystrophic epidermolysis bullosa (RDEB) treatment using genetically reprogrammed skin cells.
Explore how CRISPR-Cas9 gene editing is transforming treatment for inherited retinal diseases like LCA and retinitis pigmentosa through groundbreaking clinical trials.